Fewer than a tenth of individuals that would benefit from GLP-1 drugs including Wegovy can access them, caution the World Health Organization as it publishes its inaugural advice on the therapies.
Given in excess of 1,000,000,000 individuals worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.
According to estimates, more than two billion will be living with obesity by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a lifelong illness that can be treated with comprehensive and continuous treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are major hurdles to widespread availability to the treatments that can assist patients in reducing significant body mass, says the organization.
Skinny Jab Supply Crisis
Even under the present most favorable case, the supply of these medications could only cover about 100 million people – fewer than 10% of those who need them, as stated by the health organization.
The guideline urges countries and companies to widen availability, by strategies like patent sharing.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.
How Obesity Injections Operate
These medications imitate a natural hormone to delay gastric emptying, curb appetite and enhance the sense of being full so users reduce food intake.
Individuals commonly begin shedding pounds within a few weeks of starting on the once-weekly jabs.
Evidence suggests people may regain a significant portion within a year of stopping the medication, when their typical hunger come back.
To be above a healthy weight elevates your risk for experiencing health problems, such as diabetes, heart disease, stroke, and some malignancies.
Obesity impacts individuals in all nations and was linked to millions of fatalities worldwide in 2024, as per the WHO.
